Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Cost of Revenue (2018 - 2025)

Historic Cost of Revenue for Sunshine Biopharma (SBFM) over the last 8 years, with Q3 2025 value amounting to $6.3 million.

  • Sunshine Biopharma's Cost of Revenue rose 1390.93% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year increase of 959.54%. This contributed to the annual value of $24.2 million for FY2024, which is 5364.4% up from last year.
  • Per Sunshine Biopharma's latest filing, its Cost of Revenue stood at $6.3 million for Q3 2025, which was up 1390.93% from $6.0 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Cost of Revenue ranged from a high of $6.9 million in Q2 2024 and a low of $18515.0 during Q2 2021
  • In the last 5 years, Sunshine Biopharma's Cost of Revenue had a median value of $3.6 million in 2023 and averaged $3.2 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 401509.81% in 2023, then plummeted by 1381.13% in 2025.
  • Sunshine Biopharma's Cost of Revenue (Quarter) stood at $61289.0 in 2021, then soared by 3568.92% to $2.2 million in 2022, then skyrocketed by 127.34% to $5.1 million in 2023, then grew by 27.19% to $6.5 million in 2024, then decreased by 2.43% to $6.3 million in 2025.
  • Its Cost of Revenue was $6.3 million in Q3 2025, compared to $6.0 million in Q2 2025 and $6.2 million in Q1 2025.